5 Jan 2018 17:04
The following amendments have been made to the 'Director Dealings' announcement released on 5 January at 13.19 under RNS No 1273B.
In the PDMR dealing disclosure form, the price paid per share should have been described as £0.05 rather than £539.55, and the place of the transaction should have been described as Off Market rather than London Stock Exchange, AIM. All other details remain unchanged.
The full amended text is shown below.
5 January 2018
Diurnal Group plc
("Diurnal" or the "Company")
Replacement - Director Dealings
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that Non-Executive Director, John Goddard, has acquired 10,791 recently vested shares at £0.05 per share.
As published in the Company's AIM Admission Document, published on 21 December 2015, and in connection with his recruitment, John Goddard was awarded 32,374 ordinary shares of £0.05 each for which Mr Goddard will pay the nominal value for each share. The award of shares vest in thirds 18, 24 and 36 months from 24 December 2015, being the date of admission to AIM. There are no other performance criteria.
John Goddard's interest in the Company is now as follows:
Name | Position | Total number of conditional shares now held | Total number of ordinary shares now held |
John Goddard | Non-Executive Director | 10,792 | 37,774 |
For further information, please visit www.diurnal.co.uk or contact: | |
Diurnal Group plc | +44 (0)20 3727 1000 |
Martin Whitaker, Chief Executive Officer | |
Richard Bungay, Chief Financial Officer | |
Numis Securities Ltd (Nominated Adviser) | +44 (0)20 7260 1000 |
Nominated Adviser: Michael Meade, Paul Gillam, Freddie Barnfield | |
Corporate Broking: James Black | |
Panmure Gordon (UK) Limited (Joint Broker) | +44 (0) 20 7886 2500 |
Corporate Finance: Freddy Crossley | |
Corporate Broking: Tom Salvesen | |
FTI Consulting | +44 (0)20 3727 1000 |
Simon Conway | |
Victoria Foster Mitchell | |
Notes to Editors
About Diurnal Group plc
Founded in 2004, Diurnal is a UK-based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.
For further information about Diurnal, please visit www.diurnal.co.uk
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Name
| John Goddard | |||
2
| Reason for the notification
| ||||
a)
| Position/status
| Non-Executive Director | |||
b)
| Initial notification /Amendment
| Initial notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
| Name
| Diurnal Group plc | |||
b)
| LEI
| 213800I2HNUNZN1LDH29 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument | Ordinary shares of 5p each | |||
Identification code | GB00BDB6Q760 | ||||
b)
| Nature of the transaction
| Purchase of shares | |||
c)
| Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
£0.05 | 10,791 | ||||
d)
| Aggregated information | ||||
- Aggregated volume | 10,791 | ||||
- Price | £539.55 | ||||
e)
| Date of the transaction
| 5 January 2018 | |||
f)
| Place of the transaction
| Off Market | |||
DNL.L (DNL)